Rare Disease News

Privacy Protection in Whole Genome Sequencing

Published January 15, 2013 by NORD

Categorized in -

Whole genome sequencing (WGS) is the genetic test that determines the order of all 3 billion letters in a person’s DNA, and is a technology that has become well known …

Continue reading “Privacy Protection in Whole Genome Sequencing”

Can IBM Watson Replace Dr. Dhaliwal? Probably Not!

Published December 6, 2012 by NORD

Categorized in -

Everyone in the rare disease community who watched IBM’s “Watson” computer perform on “Jeopardy” early this year probably started to wonder about the potential of “Watson-like” systems to assist doctors …

Continue reading “Can IBM Watson Replace Dr. Dhaliwal? Probably Not!”

Patients Will Benefit From New Public-Private Partnership

Published December 3, 2012 by NORD

Categorized in -

FDA Commissioner Margaret Hamburg, MD, today announced a new public-private partnership to develop regulatory science that will speed patient access to new medical device technologies. This is the first public-private …

Continue reading “Patients Will Benefit From New Public-Private Partnership”

Glybera Becomes First-ever Gene Therapy Approved in Europe

Published November 2, 2012 by NORD

Categorized in -

According to a report on the BBC News web site today, the European Commission has — for the very first time anywhere in the Western world — given final approval …

Continue reading “Glybera Becomes First-ever Gene Therapy Approved in Europe”

Creative Collaborations May Be Key to Reducing Chemotherapy Risks

Published October 31, 2012 by NORD

Categorized in -

My friend’s 18-year-old son died recently following a 6-month battle with acute myeloid leukemia. There are many different stories I could tell about Tucker’s experience that are all too familiar …

Continue reading “Creative Collaborations May Be Key to Reducing Chemotherapy Risks”

Rare Disease News

Privacy Protection in Whole Genome Sequencing

Can IBM Watson Replace Dr. Dhaliwal? Probably Not!

Patients Will Benefit From New Public-Private Partnership

Glybera Becomes First-ever Gene Therapy Approved in Europe

Creative Collaborations May Be Key to Reducing Chemotherapy Risks

Access State Report Card Data